Nivolumab + Ipilimumab + Pemetrexed + Cisplatin + Carboplatin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Carcinoma
Conditions
Non-Small-Cell Lung Carcinoma
Trial Timeline
Mar 17, 2017 → Oct 17, 2022
NCT ID
NCT02864251About Nivolumab + Ipilimumab + Pemetrexed + Cisplatin + Carboplatin
Nivolumab + Ipilimumab + Pemetrexed + Cisplatin + Carboplatin is a phase 3 stage product being developed by Ono Pharmaceutical for Non-Small-Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02864251. Target conditions include Non-Small-Cell Lung Carcinoma.
What happened to similar drugs?
7 of 20 similar drugs in Non-Small-Cell Lung Carcinoma were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02864251 | Phase 3 | Completed |
| NCT02899299 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Carcinoma